

<https://helda.helsinki.fi>

---

Leukotriene signaling via ALOX5 and cysteinyl leukotriene  
receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-)  
stem and progenitor cells in chronic myeloid leukemia

Dolinska, Monika

2017-08-19

---

Dolinska , M , Piccini , A , Wong , W M , Gelali , E , Johansson , A-S , Klang , J , Xiao , P ,  
Yektaei-Karin , E , Stromberg , U O , Mustjoki , S , Stenke , L , Ekblom , M & Qian , H 2017 ,  
' Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in  
vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia ' ,  
Biochemical and Biophysical Research Communications , vol. 490 , no. 2 , pp. 378-384 . <https://doi.org/10.1016/j.bbrc.2017.06.051>

---

<http://hdl.handle.net/10138/217891>

<https://doi.org/10.1016/j.bbrc.2017.06.051>

---

cc\_by

publishedVersion

---

*Downloaded from Helda, University of Helsinki institutional repository.*

*This is an electronic reprint of the original article.*

*This reprint may differ from the original in pagination and typographic detail.*

*Please cite the original version.*



Contents lists available at ScienceDirect

# Biochemical and Biophysical Research Communications

journal homepage: [www.elsevier.com/locate/ybbrc](http://www.elsevier.com/locate/ybbrc)



## Leukotriene signaling via *ALOX5* and cysteinyl leukotriene receptor 1 is dispensable for *in vitro* growth of CD34<sup>+</sup>CD38<sup>−</sup> stem and progenitor cells in chronic myeloid leukemia



Monika Dolinska<sup>a</sup>, Alexandre Piccini<sup>a</sup>, Wan Man Wong<sup>b</sup>, Eleni Gelali<sup>a</sup>, Anne-Sofie Johansson<sup>a</sup>, Johannis Klang<sup>a</sup>, Pingnan Xiao<sup>a</sup>, Elham Yektaei-Karin<sup>c</sup>, Ulla Olsson Strömberg<sup>d</sup>, Satu Mustjoki<sup>e</sup>, Leif Stenke<sup>c</sup>, Marja Ekblom<sup>b</sup>, Hong Qian<sup>a,\*</sup>

<sup>a</sup> Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, SE-141 86 Stockholm, Sweden

<sup>b</sup> Department of Laboratory Medicine, Lund University, Sweden

<sup>c</sup> Department of Hematology, Karolinska University Hospital and Department of Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>d</sup> Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden

<sup>e</sup> Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

### ARTICLE INFO

#### Article history:

Received 7 June 2017

Accepted 12 June 2017

Available online 13 June 2017

#### Keywords:

Leukotriene

Leukemic stem cells

Chronic myeloid leukemia

LTC-IC

### ABSTRACT

Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) are remarkably effective inducing deep molecular remission in most patients. However, they are less effective to eradicate the leukemic stem cells (LSC), resulting in disease persistence. Therefore, there is great need to develop novel therapeutic strategies to specifically target the LSC. In an experimental mouse CML model system, the leukotriene pathway, and specifically, the expression *ALOX5*, encoding 5-lipoxygenase (5-LO), has been reported as a critical regulator of the LSC. Based on these results, the 5-LO inhibitor zileuton has been introduced in clinical trials as a therapeutic option to target the LSC although its effect on primary human CML LSC has not been studied. We have here by using multiplex single cell PCR analyzed the expression of the mediators of the leukotriene pathway in bone marrow (BM) BCR-ABL<sup>+</sup>CD34<sup>+</sup>CD38<sup>−</sup> cells at diagnosis, and found low or undetectable expression of *ALOX5*. In line with this, zileuton did not exert significant overall growth inhibition in the long-term culture-initiating cell (LTC-IC) and colony (CFU-C) assays of BM CD34<sup>+</sup>CD38<sup>−</sup> cells from 7 CML patients. The majority of the single leukemic BCR-ABL<sup>+</sup>CD34<sup>+</sup>CD38<sup>−</sup> cells expressed cysteinyl leukotriene receptors *CYSLT1* and *CYSLT2*. However, montelukast, an inhibitor of *CYSLT1*, also failed to significantly suppress CFU-C and LTC-IC growth. These findings indicate that targeting *ALOX5* or *CYSLT1* signaling with leukotriene antagonists, introduced into the clinical practice primarily as prophylaxis and treatment for asthma, may not be a promising pharmacological strategy to eradicate persisting LSC in CML patients.

© 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

### 1. Introduction

Chronic myeloid leukemia (CML) is characterized by the expression of the BCR-ABL fusion protein, a constitutively active tyrosine kinase that promotes growth of leukemic stem and progenitor cells by multiple signaling pathways involved in cell survival, proliferation and differentiation [1]. The leukemic stem cells

(LSC) in chronic phase CML reside in a phenotypically similar stem and progenitor cell population (CD34<sup>+</sup>CD38<sup>−</sup>) as normal bone marrow (BM) stem and progenitor cells [1,2] and differentiate predominantly into an expanding population of granulocytes, thrombocytes and their precursors, whereas in the terminal phase, blast crisis, immature lymphoid or myeloid progenitors accumulate as leukemic blasts.

Tyrosine kinase inhibitors (TKI) including imatinib, targeting the BCR-ABL oncoprotein, have been remarkably effective in inducing deep molecular remission in most CML patients. However, TKI are

\* Corresponding author.

E-mail address: [hong.qian@ki.se](mailto:hong.qian@ki.se) (H. Qian).

less effective in eradicating the LSC, resulting in disease persistence, most often necessitating lifelong pharmacological therapy and carrying a risk for development of drug resistance and progression to blast crisis [3]. Therefore, there is a great need to identify additional therapeutic strategies to specifically target LSC in CML.

Leukotrienes (LT) are biologically active lipid mediators involved in inflammatory processes and in malignant diseases [4,5]. The first step in LT biosynthesis is conversion of arachidonic acid by 5-lipoxygenase (5-LO). In an experimental mouse CML model, the gene encoding 5-LO, *ALOX5* was overexpressed in stem cells transfected with BCR-ABL [6], and loss of *ALOX5* in the BCR-ABL<sup>+</sup> LSC impaired the development of leukemia. Treatment with zileuton, an inhibitor of 5-LO, specifically inhibited the development of leukemia but did not inhibit the non-leukemic stem cells in this mouse model [6]. Based on these results, zileuton was proposed to be an option to eradicate the human LSC and to offer potential to improve the treatment of CML [7]. However, low levels of *ALOX5* transcript were found at diagnosis in CD34<sup>+</sup> progenitors of patients with chronic phase CML as compared to normal CD34<sup>+</sup> progenitors [8]. Its expression and function in the more primitive leukemic BCR-ABL<sup>+</sup> CD34<sup>+</sup>CD38<sup>−</sup> cells of CML patients has not been explored.

During LT biosynthesis from arachidonic acid, LTA<sub>4</sub>, an unstable intermediate product, is converted by LTA<sub>4</sub> hydrolase (LTA<sub>4</sub>H) to LTB<sub>4</sub> or by LTC<sub>4</sub> synthase (LTC<sub>4</sub>S) to cysteinyl-containing LTC<sub>4</sub>, which is further metabolized to cysteinyl LTD<sub>4</sub> and LTE<sub>4</sub>. The expression and activity of LTC<sub>4</sub>S has been shown to be increased in myeloid cells in patients with CML [9,10]. While LTB<sub>4</sub> binds to receptors BLT1 and BLT2, the cysteinyl LT act on target cells mainly through the G-protein coupled receptors CYSLT1 and CYSLT2 [5]. Recently, the expression of the CYSLT receptors in CML cell lines was reported [11], and montelukast, an inhibitor of CYSLT1, was found to suppress *in vitro* growth of CML blast crisis cell lines [11]. So far, the effects of montelukast and zileuton on the primary CD34<sup>+</sup>CD38<sup>−</sup> stem and progenitor cells from patients with CML have not been reported, even though zileuton, combined with TKI has already been introduced into clinical trials in CML ([clinicaltrials.com](https://clinicaltrials.com), NCT02047149, NCT01130688) with as yet no available efficacy data.

To assess the expression and function of LT signaling molecules in leukemic CD34<sup>+</sup>CD38<sup>−</sup> BM cells we have here employed multiplex single cell PCR and *in vitro* stem and progenitor cell assays using the LT inhibitors zileuton and montelukast, and cells from newly diagnosed CML patients. We found a low frequency of *ALOX5*-expressing CD34<sup>+</sup>CD38<sup>−</sup> cells in the CML patient samples, and no significant overall growth suppression of BM CD34<sup>+</sup>CD38<sup>−</sup> cells from CML patients by zileuton in the long-term culture-initiating cell (LTC-IC) and colony (CFU-C) assays. Although the majority of the leukemic BCR-ABL<sup>+</sup>CD34<sup>+</sup>CD38<sup>−</sup> cells expressed CYSLT1 and CYSLT2 receptors, montelukast failed to significantly inhibit growth of CML BM CD34<sup>+</sup>CD38<sup>−</sup> cells. These data suggest that targeting *ALOX5* or CYSLT1 signaling with leukotriene signaling antagonists may not be a promising pharmacological strategy to eradicate CML LSC in patients in the clinic.

## 2. Materials and methods

### 2.1. Human sample collection and CD34<sup>+</sup>CD38<sup>−</sup> cell sorting by FACS

BM aspirates collected from healthy adult volunteers and newly diagnosed patients with chronic phase CML ( $n = 10$ , Table S1) were used in accordance with approved protocols (LU-195-00, LU-826-2004, 2012/4:10 and 2013/3:1). The WHO criteria for chronic phase CML were employed [12]. Mononuclear cells were isolated by Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AS, Oslo, Norway).

The CD34<sup>+</sup> cells were enriched by using CD34 MicroBead Kit (Miltenyi Biotech, Bergisch Gladbach, Germany). The CD34<sup>+</sup> or CD34<sup>+</sup>CD38<sup>−</sup> cells were further sorted by FACSARIAIII Cell Sorter (BD Biosciences) after staining with monoclonal antibodies (BD Biosciences, San Jose, CA, USA), anti-CD34-FITC or APC (8G12) and anti-CD38-PECY7 or PE (HB7). The gates were set according to fluorescence-minus-one controls. The dead cells were excluded by propidium iodide (PI; Invitrogen) staining.

### 2.2. Reagents

Imatinib and leukotriene antagonists were provided by Cayman Chemical Company (Ann Arbor, MI, USA). Stock solutions were prepared with DMSO (imatinib 10 mM, montelukast 50 mM and zileuton 100 mM). The final concentrations used in cultures were imatinib 1 or 5  $\mu$ M, and zileuton and montelukast 20  $\mu$ M.

### 2.3. Colony assays

The purified CD34<sup>+</sup>CD38<sup>−</sup> or CD34<sup>+</sup> cells were cultured at a density of 150 cells/dish (for CD34<sup>+</sup> cells) or 50 cells/dish (for CD34<sup>+</sup>CD38<sup>−</sup> cells) in Methocult H4435 (Stem Cell Technologies) in duplicate. The colony-forming units in culture (CFU-Cs) were counted at day 14.

### 2.4. LTC-IC assay

LTC-IC assay was performed as described [13,14]. The CD34<sup>+</sup>CD38<sup>−</sup> cells were sorted directly and plated in 200  $\mu$ L Myelocult H5100 (Stem Cell Technologies),  $10^{-6}$  M hydrocortisone (Sigma) in Collagen I coated or plain 96-well microplates (BD Biosciences) on irradiated (8000 cGy) murine stromal cell line M2-10B4 (10000 cells/well), engineered to express human cytokines, IL-3 and G-CSF [13]. The cells were seeded at 3, 10, 30 and 100 cells/well or 1, 3, 10 and 30 cells/well, 10–18 replicates except for 30 or 100 cells/well where a small total cell number in some cases restricted the number of replicates. Imatinib and/or leukotriene antagonists or DMSO in the corresponding final concentration as in the inhibitors, were added at the initiation of the cultures, and the cultures were maintained at 37 °C and 5% CO<sub>2</sub> for 6 weeks with weekly half-medium change. Thereafter 140  $\mu$ L of the medium was carefully removed and the wells were overlaid with 150  $\mu$ L Methocult H4435/well. The wells were scored as positive or negative after 14 days, and the frequencies of LTC-IC were calculated using the L-Calc software (StemCell Technologies).

### 2.5. Multiplex single-cell RT-PCR analysis

Single-cell RT-PCR analysis was performed as previously described [15]. The CD34<sup>+</sup>CD38<sup>−</sup> CML cells were deposited directly at 1 cell/well in 4  $\mu$ L of lysis buffer (dNTPs, DTT, 10% NP40, RNase inhibitor) per well in 96-well plates (Thermo Scientific, #AB-0800). Cell lysates were reverse transcribed using multiple pairs of gene-specific reverse primers and 50U MMLV-RT per reaction in the buffer provided by the supplier (200 U/ml, Life technologies). The first-round PCR with 35 cycles was performed by addition of 40  $\mu$ L PCR buffer and 1.25 U Taq polymerase (TaKaRa kit, Clontech). One microliter aliquots of first-round PCRs were further amplified using fully nested gene-specific primers. Aliquots of second-round PCR products were subjected to gel electrophoresis and visualized by GelRed™ staining (Invitrogen) on 1.5–3% agarose gel. The expression of BCR/ABL and the leukotriene pathway genes (*CYSLT1*, *CYSLT2*, *ALOX5*, and *LTA4H*) were analyzed simultaneously with *HPRT*, a reference gene. The wells were defined as positive for containing one cell if they were positive for *HPRT* gene product, or

for two of other genes in the GelRed™ stained agarose gel if negative for *HPRT*. The primer sequences are listed in Table S2.

## 2.6. Statistics

Statistical differences were evaluated by Wilcoxon matched-pairs signed rank test. The two-sided *p*-value was considered to be significant when *p* < 0.05.

See supplemental materials for additional methods.


## 3. Results

### 3.1. Expression of LT signaling molecules in single CML CD34<sup>+</sup>CD38<sup>−</sup>BCR-ABL<sup>+</sup> cells

To specifically analyze the expression of LT signaling molecules in LSC, we determined the co-expression of *BCR-ABL* with LT pathway mediators *ALOX5*, *CYSLTR1*, *CYSLTR2* and *LTA4H* mRNA in single BM CD34<sup>+</sup>CD38<sup>−</sup> cells from 8 CML patients (Table S1) by using nested RT-PCR (Fig. 1). The frequencies of the *BCR-ABL*<sup>+</sup> cells were 38%–70% of the CD34<sup>+</sup>CD38<sup>−</sup> cells (Figs. 1C and 2A). Notably, *ALOX5* was undetectable in one BM sample and was expressed only in a small fraction of leukemic *BCR-ABL*<sup>+</sup>CD34<sup>+</sup>CD38<sup>−</sup> cells in most BM samples with a median frequency of 10.6% (Fig. 2). The median frequency of residual nonleukemic *BCR-ABL*<sup>−</sup> cells expressing *ALOX5* was similarly low (16.0%). The expression of *LTA4H* was overall high with median frequencies of 95.6% and 79.6% in the *BCR-ABL*<sup>+</sup> and *BCR-ABL*<sup>−</sup> cells, respectively (Fig. 2B). The cysteinyl LT receptors *CYSLTR1* and *CYSLTR2* were also expressed in most *BCR-ABL*<sup>+</sup> LSC (median frequency of 64.5% and 57.3%, respectively) and *BCR-ABL*<sup>−</sup> CD34<sup>+</sup>CD38<sup>−</sup> cells (median frequency of 71.7% and 81.7%, respectively) (Fig. 2B).

### 3.2. Growth response of CML CD34<sup>+</sup>CD38<sup>−</sup>BCR-ABL<sup>+</sup> cells to imatinib and LT signaling inhibitors in LTC-IC assay

To test the functional response of the primitive leukemic stem and progenitor cells to the LT inhibitors zileuton or montelukast alone and in combination with imatinib, we performed limiting dilution LTC-IC assay of BM CD34<sup>+</sup>CD38<sup>−</sup> cells from 7 CML patients and 5 healthy donors (Fig. 3). The median frequencies of LTC-IC in BM CD34<sup>+</sup>CD38<sup>−</sup> cells from CML patients and normal BM donors were 0.38 and 0.40, respectively, in agreement with a previous report [17]. Imatinib induced a reduction of LTC-IC frequencies in CD34<sup>+</sup>CD38<sup>−</sup> cells from 6 out of 7 tested CML patient samples, representing a significant overall growth inhibition (median of 0.12, *p* = 0.03) (Fig. 3A, C). In contrast to imatinib, neither zileuton nor montelukast were able to induce significant overall inhibition of LTC-IC growth of the 7 tested CML BM samples (Fig. 3A), although some reductions were observed in CML5 by 38.2% and in CML8 by 53% compared to the DMSO control. Similarly, no significant additive inhibition could be detected when the LT inhibitors were combined with imatinib (Fig. 3A,C). However, in a BM sample (CML8) from a patient who progressed to blast crisis soon after diagnosis (Table S1), zileuton in combination with imatinib seemed to further suppress LTC-IC activity of the CD34<sup>+</sup>CD38<sup>−</sup> cells with the LTC-IC frequency reduced from 0.031 in zileuton alone to 0.018 in zileuton plus imatinib (Fig. 3A). Cytopenias are known off-target effects of imatinib, and inhibition of LTC-IC activity by imatinib was seen in some healthy donor BM CD34<sup>+</sup>CD38<sup>−</sup> cells. Although some inhibition by zileuton and montelukast, comparable to that observed in few CML samples, was seen in the LTC-IC assays of few normal BM samples, there was no significant overall decrease in LTC-IC frequencies in the normal BM in cultures with imatinib, LT inhibitors or the combination (Fig. 3B,D).



**Fig. 1.** Multiplex single cell RT-PCR analysis showing expression of leukotriene signaling molecules in *BCR-ABL*<sup>+</sup> and *BCR-ABL*<sup>−</sup>CD34<sup>+</sup>CD38<sup>−</sup> cells of CML patients.


(A) Experimental setup for nested-PCR and *in vitro* function inhibition assays of CML stem and progenitor cells to LT inhibitors. The CD34<sup>+</sup>CD38<sup>−</sup> cells were sorted for single cell PCR analysis and for LTC-IC assay. For single cell PCR, the cells were deposited directly in 96-well plates at 1 cell/well and subjected to cDNA synthesis followed by two-round multiplex nested PCR to amplify the genes. The electrophoresis was run to identify the specific RT-PCR products.

(B) FACS profile for sorting of CML CD34<sup>+</sup>CD38<sup>−</sup> cells. The cells were gated for live PI<sup>−</sup> CD34<sup>+</sup> cells and subsequently gated for CD34<sup>+</sup>CD38<sup>−</sup> cells.

(C) The frequencies of *BCR-ABL*<sup>+</sup> cells within the CD34<sup>+</sup>CD38<sup>−</sup> cells in the CML patients detected by single cell PCR.

(D) Representative image of RT-PCR products for *CYSLTR1*, *CYSLTR2*, *ALOX5*, *LTA4H* and *HPRT*.





**Fig. 2.** Expression pattern of leukotriene signaling molecules in single  $CD34^+CD38^-$  cells from 8 newly diagnosed CML patients.

(A) Color-coated maps show co-expression pattern of *BCR-ABL*, *HPRT*, *LTA4H*, *CYSLTR1*, *CYSLTR2* and *ALOX5* mRNA in single  $CD34^+CD38^-$  cells from CML patients. *HPRT* was used a reference gene. The color-coated squares indicate that an RT-PCR product for the indicated genes could be detected on GelRed-stained agarose gel. Each row represents a single cell. The numbers at bottom of the panel indicate the number of cells expressing the indicated gene and total number of the cells analyzed. The cells from patient 2 were isolated from blood.

(B) *ALOX5*, *CYSLTR1*, *CYSLTR2* and *LTA4H*, expression within the leukemic *BCR-ABL*<sup>+</sup> and non-leukemic *BCR-ABL*<sup>-</sup>  $CD34^+CD38^-$  BM cells from 7 patients and blood cells from 1 patient (patient 2) with CML.

### 3.3. No overall significant inhibition of CFU-C from CML $CD34^+$ cells by zileuton or montelukast

CFU-C assays were performed on  $CD34^+$  cells from 5 CML patients (Fig. 3E). Not surprisingly, total CFU-Cs were dramatically suppressed by imatinib in all 9 assays of 6 patient samples ( $p = 0.03$ ), in agreement with the reported more efficient suppression by imatinib of less primitive leukemic progenitor cells [18]. Inhibition of CFU-C growth by imatinib was similar at 1  $\mu$ M and 5  $\mu$ M (Fig. S1). There was no significant inhibition in the colony growth by montelukast or zileuton.

### 3.4. Residual *BCR-ABL*<sup>+</sup> cells were detected in single colonies from LTC-IC cultures

In order to determine whether the LT inhibitors could specifically target the LSC in the LTC-IC cultures, we analyzed cells from these cultures by FISH for the *BCR-ABL* fusion gene. We could detect residual *BCR-ABL*<sup>+</sup> cells after all treatments (Fig. 4), showing that even when total LTC-IC frequencies were reduced by imatinib (Patients CML3, 7, and 9, Fig. 3), LSCs were not fully eradicated.


## 4. Discussion

Signaling pathways mediated by leukotrienes have been identified as important regulators of acute and chronic inflammation, but are also involved in the pathogenesis in several types of cancers, including colon, lung, prostate and breast cancers. In line with this, studies using *in vivo* murine colon cancer xenograft models have


demonstrated notable potential of both zileuton and montelukast as anti-cancer agents, suggesting that inhibiting LT signaling may be a promising additional pharmacological strategy to target these tumors [19].

The role of LT signaling in human normal hematopoiesis and leukemia remains elusive. The receptor for LTB<sub>4</sub>, BLT1 is expressed in  $CD34^+$  cells in CML at diagnosis and its expression appeared to be correlated with the clinical response to imatinib [8]. In addition, the other LTB<sub>4</sub> receptor BLT2 was found to be upregulated by *BCR-ABL* in primary CML blast crisis  $CD34^+$  progenitors, and inhibition of this receptor suppressed proliferation and induced apoptosis of the leukemic cells [20]. High expression of *CYSLTR1* was reported in chronic lymphocytic leukemia, and *in vitro* inhibition of it induced apoptosis of the leukemic cells, suggesting this receptor as a potential therapeutic target [21].

Based on these reports suggesting a role for 5LO/*ALOX5* and/or cysteinyl LT signaling in solid cancers and in leukemia, we have here focused on the expression of the target molecules of these two respective inhibitors zileuton and montelukast in primary *BCR-ABL*<sup>+</sup>  $CD34^+CD38^-$  LSC from CML patient at diagnosis and their *in vitro* functional response to these inhibitors. We show by single cell PCR assays that *CYSLTR1* receptor is expressed in most leukemic and residual normal  $CD34^+CD38^-$  cells in BM of CML patients. We also find the expression of the *CYSLTR2* in most of these cells, with a partially overlapping expression with *CYSLTR1* receptor. *CYSLTR1* mRNA has previously been shown to be expressed in normal hematopoietic  $CD34^+$  progenitors, and signaling via *CYSLTR1* modulated adhesion, proliferation and transmigration of the progenitors *in vitro* [22,23], while the role of *CYSLTR2* in hematopoiesis is so far



**Fig. 3. Functional response of BM hematopoietic stem and progenitor cells from patients with CML and healthy donors to imatinib and leukotriene inhibitors in LTC-IC and CFU-C assays.** (A–D) The growth response of CML (A, C) and normal BM (B, D) CD34<sup>+</sup>CD38<sup>−</sup> cells to imatinib (IM) zileuton (ZIL), montelukast (MON) and combination of IM with leukotriene inhibitors in LTC-IC assay. The data are from 7 newly diagnosed CML patients and 5 normal BM donors. (E) The growth response of CML CD34<sup>+</sup> cells to IM, ZIL and MON in CFU-C colony assays. Data are the numbers of CFU-C per 150 CD34<sup>+</sup> BM (circle) and PB (square) cells of 5 indicated CML patients. Each dot represents mean of duplicate measurements in the colony assays. \**p* < 0.05 Wilcoxon matched-pairs signed rank test, compared to DMSO control. Horizontal bars show the median values.



**Fig. 4. FISH analysis of BCR-ABL fusion gene expression in the cells derived from the LTC-IC assay shows the residual BCR-ABL<sup>+</sup> cells after treatment with imatinib and leukotriene inhibitors zileuton and montelukast.** The cells from individual LTC-IC culture wells were picked and transferred to microscopic slides by cytopspin for the FISH analysis. (A) The representative images of the BCR-ABL<sup>+</sup> cells derived from the colonies in culture wells. (B) The frequencies of the BCR-ABL<sup>+</sup> cells in wells after LTC-IC cultures from 4 patients. At least 55 cells in total in each sample were counted for calculating the frequency of the BCR-ABL<sup>+</sup> cells.

unclear.

By single cell PCR analysis we detected a very low overall frequency of *ALOX5* expression in the primitive *BCR-ABL*<sup>+</sup> *CD34*<sup>+</sup> *CD38*<sup>−</sup> LSC and *BCR-ABL*<sup>−</sup> *CD34*<sup>+</sup> *CD38*<sup>−</sup> nonleukemic cells of CML patients, suggesting distinct regulation and functional importance of 5-LO/*ALOX5* in primitive human CML LSC and in the mouse *BCR-ABL*<sup>+</sup> LSC. However, the expression of downstream *LT4H* in most leukemic and nonleukemic cells may indicate transcellular biosynthesis of LT downstream of 5-LO in the LSC, as reported in other cell types [24].

In the *in vitro* functional stem and progenitor cell assays of primary *CD34*<sup>+</sup> *CD38*<sup>−</sup> cells of CML patients, imatinib significantly inhibited the overall LTC-IC activity in leukemic, but not in normal donor BM samples, supporting a specific inhibitory effect on *BCR-ABL*<sup>+</sup> LSC in these culture systems. Imatinib also significantly inhibited CFU-C growth of the leukemic BM progenitors. In contrast, zileuton, did not induce any significant overall inhibition in the LTC-IC activity of *CD34*<sup>+</sup> *CD38*<sup>−</sup> cells or the CFU-C activity of *CD34*<sup>+</sup> cells of the CML patient BM samples. Our data suggest that targeting the *ALOX5* gene product, 5-LO using zileuton to treat CML may not be as promising as expected from previously reported mouse studies.

In contrast to the reported inhibition of the growth of CML blast crisis cell lines by montelukast in a short term liquid culture assay [11], we did not find significant overall growth suppression of BM *CD34*<sup>+</sup> *CD38*<sup>−</sup> or *CD34*<sup>+</sup> stem and progenitor cells of CML patients by montelukast in LTC-IC or CFU-C assays, suggesting that pharmacological inhibition of CYSLTR1 may not either be a promising therapeutic strategy for eradicating CML LSC.

In summary, our findings indicate that the LT signaling pathway via *ALOX5* or CYSLTR1 may be less important for survival of primary human CML LSCs than that of mouse *BCR-ABL*<sup>+</sup> cells or CML blast cell lines. Consequently, inhibiting 5-LO or CYSLTR1 by zileuton and montelukast may not be a promising option to eradicate CML LSC. However, the expression and functional role of several other mediators of the LT pathway in human primitive hematopoietic stem and progenitor cells and their leukemic counterparts in CML remains elusive and should be assessed in further studies.

## Conflict of interest

M.E., L.S., S.M., U.O.S. have participated as investigators in several international clinical CML studies sponsored by pharmaceutical companies (Novartis, BMS, Pfizer and Ariad), generating remuneration to these individuals or to their respective institutions/departments. Other authors declare no competing financial interest regarding this study.

## Acknowledgements

This study was supported by research funding from Swedish Cancer Society (CAN 2012/891, CAN2015/652), Dr. Åke Olsson Foundation, Swedish Research Council (2012–2070), The Cancer Society in Stockholm and the King Gustaf V's Jubilee Foundation (Radiumhemmet 131192 and 151241), The Swedish Childhood Cancer Society (FoAss13/015, PROJ12/081) and Karolinska Institute Wallenberg Institute for Regenerative Medicine to HQ and Swedish Cancer Society (CAN 2010/590), Swedish Research Council (2008–19616–59131–19), Medical Faculty, Lund University, Skåne University Hospital, Gunnar Nilsson Foundation, John Persson Foundation, Gunnel Björk Foundation and Georg Danielsson Foundation to ME, and Finnish Cancer Institute, Finnish Cancer Societies and Signe and Ane Gyllenberg Foundation to SM.

MD, AP, ME and HQ have participated in conception and design, performing experiments, collection and assembly of data, data

analysis and interpretation and manuscript writing. EG, WMW, JK and ASJ performed experiments, collected data. PX, LS, SM, EYK and UOS, contributed to data analysis and interpretation. All authors have approved the final version of the manuscript.

## Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.bbrc.2017.06.051>.

## Transparency document

Transparency document related to this article can be found online at <http://dx.doi.org/10.1016/j.bbrc.2017.06.051>.

## References

- [1] M. Savona, M. Talpaz, Getting to the stem of chronic myeloid leukaemia, *Nat. Rev. Cancer* 8 (2008) 341–350.
- [2] H. Zhou, R. Xu, Leukemia stem cells: the root of chronic myeloid leukemia, *Protein Cell* 6 (2015) 403–412.
- [3] R. Bhatia, M. Holtz, N. Niu, R. Gray, D.S. Snyder, C.L. Sawyers, D.A. Arber, M.L. Slovak, S.J. Forman, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment, *Blood* 101 (2003) 4701–4707.
- [4] J.M. Poczobutt, T.T. Nguyen, D. Hanson, H. Li, T.R. Sippel, M.C. Weiser-Evans, M. Gijon, R.C. Murphy, R.A. Nemenoff, Deletion of 5-lipoxygenase in the tumor microenvironment promotes lung cancer progression and metastasis through regulating T cell recruitment, *J. Immunol.* 196 (2016) 891–901.
- [5] M. Peters-Golden, W.R. Henderson Jr., Leukotrienes, *N. Engl. J. Med.* 357 (2007) 1841–1854.
- [6] Y. Chen, Y. Hu, H. Zhang, C. Peng, S. Li, Loss of the *Alox5* gene impairs leukemia stem cells and prevents chronic myeloid leukemia, *Nat. Genet.* 41 (2009) 783–792.
- [7] T. O'Hare, M.S. Zabriskie, A.M. Eiring, M.W. Deininger, Pushing the limits of targeted therapy in chronic myeloid leukaemia, *Nat. Rev. Cancer* 12 (2012) 513–526.
- [8] C.M. Lucas, R.J. Harris, A. Giannoudis, E. McDonald, R.E. Clark, Low leukotriene B4 receptor 1 leads to *ALOX5* downregulation at diagnosis of chronic myeloid leukemia, *Haematologica* 99 (2014) 1710–1715.
- [9] C. Roos, L. Stenke, L. Ohm, S. Widell, M. Kumlin, J.A. Lindgren, S. Tornhamre, Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia, *Br. J. Haematol.* 142 (2008) 992–995.
- [10] M. Sjolinder, L. Stenke, B. Nasman-Glaser, S. Widell, J. Doucet, P.J. Jakobsson, J.A. Lindgren, Aberrant expression of active leukotriene C(4) synthase in CD16(+) neutrophils from patients with chronic myeloid leukemia, *Blood* 95 (2000) 1456–1464.
- [11] E. Yektai-Karin, A. Zovko, A. Nilsson, B. Nasman-Glaser, L. Kanter, O. Radmark, J. Wallvik, M. Ekblom, M. Dolinska, H. Qian, L. Stenke, Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia, *Leuk. Lymphoma* (2016) 1–11.
- [12] M. Baccarani, M.W. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J.F. Apperley, F. Cervantes, R.E. Clark, J.E. Cortes, F. Guilhot, H. Hjorth-Hansen, T.P. Hughes, H.M. Kantarjian, D.W. Kim, R.A. Larson, J.H. Lipton, F.X. Mahon, G. Martinelli, J. Mayer, M.C. Muller, D. Niederwieser, F. Pane, J.P. Radich, P. Rousselot, G. Saglio, S. Saussele, C. Schiffer, R. Silver, B. Simonsson, J.L. Steegmann, J.M. Goldman, R. Hehlmann, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, *Blood* 122 (2013) 872–884.
- [13] D.E. Hogge, P.M. Lansdorp, D. Reid, B. Gerhard, C.J. Eaves, Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor, *Blood* 88 (1996) 3765–3773.
- [14] W.M. Wong, M. Dolinska, M. Sigvardsson, M. Ekblom, H. Qian, A novel Lin-*CD34*<sup>+</sup> *CD38*<sup>−</sup> integrin  $\alpha 2^+$  bipotential megakaryocyte-erythrocyte progenitor population in the human bone marrow, *Leukemia* 30 (2016) 1399–1402.
- [15] H. Qian, A. Badaloni, F. Chiara, J. Stjernberg, N. Polissetti, K. Nihlberg, G.G. Consalez, M. Sigvardsson, Molecular characterization of prospectively isolated multipotent mesenchymal progenitors provides new insight into the cellular identity of mesenchymal stem cells in mouse bone marrow, *Mol. Cell. Biol.* 33 (2013) 661–677.
- [17] Y. Zhao, A. Delaney, A. Raouf, K. Raghuram, H.I. Li, A. Schnerch, X. Jiang, A.C. Eaves, A.A. Marra, C.J. Eaves, Differentially expressed and novel transcripts in highly purified chronic phase CML stem cells, *Blood* 112 (2008) 193. ASH abstract.
- [18] X. Jiang, Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, A. Eaves, C. Eaves, Chronic myeloid leukemia stem cells possess multiple unique features of resistance to *BCR-ABL* targeted therapies, *Leukemia* 21 (2007) 926–935.

- [19] L. Burke, C.T. Butler, A. Murphy, B. Moran, W.M. Gallagher, J. O'Sullivan, B.N. Kennedy, Evaluation of cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer, *Front. Cell Dev. Biol.* 4 (2016) 103.
- [20] M. Xiao, H. Ai, T. Li, P. Rajoria, P. Shahu, X. Li, Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function, *Biochem. Biophys. Res. Commun.* 472 (2016) 610–616.
- [21] A.C. Drost, G. Seitz, A. Boehmler, M. Funk, K.P. Norz, A. Zipfel, X. Xue, L. Kanz, R. Mohle, The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia, *Leuk. Lymphoma* 53 (2012) 665–673.
- [22] F. Bautz, C. Denzlinger, L. Kanz, R. Mohle, Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1, *Blood* 97 (2001) 3433–3440.
- [23] A.M. Boehmler, A. Drost, L. Jaggy, G. Seitz, T. Wiesner, C. Denzlinger, L. Kanz, R. Mohle, The CysLT1 ligand leukotriene D4 supports alpha4beta1- and alpha5beta1-mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells, *J. Immunol.* 182 (2009) 6789–6798.
- [24] S. Zarini, M.A. Gijon, A.E. Ransome, R.C. Murphy, A. Sala, Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation, *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) 8296–8301.